Aarey Drugs & Pharmaceuticals Limited Shareholders Approve All Resolutions at 35th AGM
The announcement details the routine approval of all standard resolutions at the 35th AGM, including financial statements, re-appointments of directors and auditors, and related party transactions. These are typical corporate governance matters and do not signify a major strategic shift, new business venture, or significant financial event, thus having a low immediate impact on the company's valuation or operations.
All proposed resolutions at the 35th Annual General Meeting were approved by the shareholders with an overwhelming majority (approximately 99.9998% in favour), indicating strong shareholder support for the company's proposals.
Aarey Drugs & Pharmaceuticals Limited announced the voting results along with the Consolidated Scrutinizer's Report for its 35th Annual General Meeting (AGM) held on Monday, 29 September 2025. All resolutions proposed at the AGM were passed by the shareholders with an overwhelming majority.
Key resolutions approved include: * Adoption of the audited financial statements for the year ended 31 March 2025, along with the Directors' and Auditors' reports thereon. * Re-appointment of Mr. Mihir Ghatalia (DIN: 00581005) as a Director, who retired by rotation. * Re-appointment of M/S. Motilal & Associates (ICAI Firm Registration no.: 106584W) as Statutory Auditors for a second term of five years. * Re-appointment of Mr. Chetan K Mehta (DIN: 01639366) as an Independent Director for a second term of 5 years. * Appointment of M/S. Ashika Shetty (COP No.: 27779) as the Secretarial Auditor of the company. * Continuation of directorship of Mr. Nimit Ghatalia (DIN: 07069841) as an Executive Director. * Approval of Related Party Transactions.
The voting process included remote e-voting prior to the AGM and e-voting during the AGM, with the cut-off date for shareholders to vote being Monday, 22 September 2025. The overall voting results showed approximately 99.9998% of votes polled were in favour of the resolutions.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.